Mitigation of Cardiovascular Disease and Toxicity through NRF2 Signalling

James A Roberts1, Richard D Rainbow1,2, Parveen Sharma1,2

  • 1Department of Cardiovascular and Metabolic Medicine, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool L7 8TX, UK.

Insights

The nuclear factor erythroid 2-related factor 2 (NRF2) pathway protects against cardiovascular disease. However, aging and certain drugs can disrupt NRF2, increasing heart toxicity and dysfunction.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Cardiology

Background:

  • Cardiovascular diseases (CVDs) significantly increase morbidity and mortality.
  • Key pathophysiological factors include disrupted reactive oxygen species (ROS) signaling, iron homeostasis, and mitochondrial function.
  • The transcription factor NRF2 regulates cytoprotective genes against oxidative and xenobiotic stresses.

Purpose of the Study:

  • To review the role of NRF2 in cardiovascular health and disease.
  • To explore how NRF2 dysregulation impacts cardiotoxicity.
  • To discuss the implications of NRF2 modulation for cardiovascular conditions.

Main Methods:

  • Literature review of NRF2 signaling pathways.
  • Analysis of NRF2's role in oxidative stress and mitochondrial function.
  • Examination of NRF2's interaction with aging and drug-induced cardiotoxicity.

Main Results:

  • NRF2 activation shows potential in alleviating cardiotoxicity and CVD progression.
  • Aging and chemotherapeutics (e.g., anthracyclines) can impair NRF2 responses.
  • Dysregulated NRF2 compromises cardiovascular system resilience.

Conclusions:

  • NRF2 is a critical regulator of cardiovascular homeostasis and stress resistance.
  • Understanding NRF2 dynamics is crucial for developing strategies against cardiotoxicity.
  • Targeting NRF2 may offer therapeutic benefits for cardiovascular diseases.

Related Concept Videos

Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
14.6K
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
7.6K
Transducer Mechanism: Nuclear Receptors01:31

Transducer Mechanism: Nuclear Receptors

Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
1.4K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
474
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
16
Regulation of the Cardiovascular System01:27

Regulation of the Cardiovascular System

The regulation of the cardiovascular system allows the body to adapt to various demands and maintain homeostasis.
The regulation of the cardiovascular system involves the autonomic nervous system (ANS), baroreceptors, and chemoreceptors, ensuring that heart rate and blood pressure are appropriately modulated in response to varying physiological demands.
The ANS comprises two main divisions: the sympathetic and parasympathetic nervous systems. The sympathetic nervous system enhances...
1.3K